Clinical trial
A Phase 4, Multicenter, Open-label, Safety and Antitumor Activity Study of Zolbetuximab Plus mFOLFOX6 or CAPOX as Firstline Treatment in Indian Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT07829757 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Multicenter, Open-label, Safety and Antitumor Activity Study of Zolbetuximab Plus mFOLFOX6 or CAPOX as Firstline Treatment in Indian Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- July 31, 2029
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced unresectable gastric adenocarcinoma or cancer, locally advanced unresectable gastroesophageal junction (gej) adenocarcinoma or cancer, metastatic gastric adenocarcinoma or cancer, metastatic gastroesophageal junction (gej) adenocarcinoma